Voncento (human coagulation factor VIII / human von willebrand factor)
- Region
- 🇪🇺 EU
- Active substance
- human coagulation factor VIII / human von willebrand factor
- Company
- CSL Behring GmbH
- Status
- Authorised
- Therapeutic area
- Hemophilia A; von Willebrand Diseases
- EU approval
- Mon 12 Aug 2013
- Application
- EMEA/H/C/002493
- ATC
- B02BD06
- Official record
- www.ema.europa.eu
Indication
Von Willebrand disease (VWD) Prophylaxis and treatment of haemorrhage or surgical bleeding in patients with VWD, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Haemophilia A (congenital factor-VIII deficiency) Prophylaxis and treatment of bleeding in patients with haemophilia A.
Regulatory milestones
No milestones recorded in the last year.
Follow Voncento
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.